Martin Vu

Dr. Martin Vu is a Health Economist at the Health Economics and Policy Research Unit within the Wolfson Institute of Population Health at Queen Mary University of London. He holds a PhD from the University of Melbourne (2023), specializing in the health economics of genomic and precision medicine. His research focuses on cost-effectiveness analyses of genomic technologies, particularly in oncology, to inform healthcare policy and equity. He has contributed to national/international discussions on genomic technology implementation.

• Education: PhD in Health Economics, University of Melbourne (2023)
• Previous roles: Research Fellow at Cancer Health Services Research, University of Melbourne; Evaluator at Melbourne Health Technology and Value Assessment Collaboration

Research interests include molecular diagnostics' cost-effectiveness, genomic resource allocation, and health policy implications of precision medicine. His work bridges economic evaluations with clinical decision-making in cancer care. Recent publications (2020–2024) emphasize genomic testing's economic impacts in leukemia treatment pathways and policy frameworks for genomic innovation.

Publications highlight trends in genomic medicine economics, including multi-criteria decision analysis for reimbursement strategies and comparative economic assessments of molecular testing approaches.

No scientific awards explicitly stated, but contributions to PBAC submissions and policy guidance demonstrate recognition of his work. No formal advising record listed.

Part of the Wolfson Institute's Centre for Evaluation and Methods, collaborating on health technology assessments and population health strategies.